How long was JUPITER's follow-up after the trial was stopped?

The randomized phase had a median follow-up of 1.9 years. The open-label extension added approximately two more years of observation, though placebo patients crossed over to rosuvastatin, making direct comparison less rigorous after unblinding.

Did the cardiovascular benefit hold up in the extension period?

Yes. Former placebo participants who started rosuvastatin saw their event rates decline toward those of the original treatment group. The combined data supported a five-year NNT of approximately 25 for one major CV event prevented.

How much did JUPITER increase diabetes risk?

In-trial, rosuvastatin was associated with a 25% relative increase in physician-reported diabetes (3.0% vs. 2.4%). The absolute excess was 0.6% over 1.9 years, concentrated in patients who already had metabolic risk factors at baseline.

Was JUPITER's early termination justified?

The independent Data Safety Monitoring Board stopped the trial per prespecified rules when the efficacy boundary was crossed. Critics argue this may have inflated the effect size by 20 to 30%. The CV benefit remains statistically and clinically significant even with conservative adjustments.

Did the FDA change the rosuvastatin label because of JUPITER?

Yes. The FDA approved a primary-prevention indication for rosuvastatin based on JUPITER in 2010 and later added warnings about increases in HbA1c and fasting blood glucose based on the diabetes signal.

Is hsCRP testing now recommended before starting a statin?

Not universally. The 2013 ACC/AHA guidelines list hsCRP as a factor that can inform shared decision-making in borderline-risk patients (5 to 7.5% 10-year ASCVD risk), but they do not mandate testing for all adults.

How does JUPITER compare with CANTOS for the inflammation hypothesis?

JUPITER showed that a statin (which lowers both LDL and CRP) reduces CV events. CANTOS used canakinumab to lower CRP without changing LDL and still reduced events, directly validating that inflammation reduction itself is cardioprotective.

Who benefits most from the JUPITER approach?

Adults over 50 (men) or 60 (women) with LDL <130 mg/dL, hsCRP ≥2 mg/L, and no pre-existing diabetes or strong prediabetic features represent the population most likely to gain net benefit from rosuvastatin initiation based on JUPITER's data.

Were there cancer signals in JUPITER's follow-up?

No. The original trial and extension data showed no significant difference in cancer incidence between rosuvastatin and placebo groups. Early imbalances in cancer diagnoses were attributed to chance and resolved with longer observation.

Has any trial replicated JUPITER's CRP-based enrollment strategy?

No large-scale RCT has used the same hsCRP ≥2 mg/L plus normal-LDL enrollment criteria. CANTOS tested a related but distinct hypothesis. JUPITER remains the only completed trial that selected primary-prevention patients specifically by elevated CRP for statin therapy.

JUPITER Extension Data and What Happened After the Trial Ended

Q: Were there cancer signals in JUPITER's follow-up?

No. The original trial and extension data showed no significant difference in cancer incidence between rosuvastatin and placebo groups. Early imbalances in cancer diagnoses were attributed to chance and resolved with longer observation.

Q: Has any trial replicated JUPITER's CRP-based enrollment strategy?

No large-scale RCT has used the same hsCRP ≥2 mg/L plus normal-LDL enrollment criteria. CANTOS tested a related but distinct hypothesis. JUPITER remains the only completed trial that selected primary-prevention patients specifically by elevated CRP for statin therapy.

By HealthRX.com Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Clinical image for JUPITER Extension Data and What Happened After the Trial Ended Image: HealthRX.com clinical image

At a glance

| Parameter | Detail | |---|---| | N | 17,802 | | Intervention | Rosuvastatin 20 mg daily | | Comparator | Placebo | | Median follow-up | 1.9 years (stopped early) | | Primary endpoint | First major cardiovascular event (MI, stroke, arterial revascularization, hospitalization for unstable angina, or CV death) | | Key result | HR 0.56 (95% CI 0.46, 0.69), 44% relative risk reduction | | Publication | Ridker et al., NEJM 2008 |

Why Follow-Up Data Matters for JUPITER

JUPITER enrolled apparently healthy men (≥50 years) and women (≥60 years) with LDL cholesterol <130 mg/dL and high-sensitivity C-reactive protein (hsCRP) ≥2.0 mg/L. The primary trial demonstrated a 44% reduction in the composite CV endpoint with rosuvastatin 20 mg versus placebo. The Data Safety Monitoring Board halted the study at a median of 1.9 years because the prespecified efficacy boundary had been crossed.

That early stop created two problems. First, short follow-up limits any assessment of rare safety signals, particularly cancer and new-onset diabetes. Second, early termination of trials tends to inflate treatment effects, a phenomenon well described in cardiovascular trial methodology. Critics argued that the true long-term benefit might be smaller than what the truncated dataset suggested.

The Post-Trial Follow-Up Cohort

After unblinding, participants originally assigned to placebo were offered open-label rosuvastatin. Ridker and colleagues published an extended follow-up analysis examining what happened during this transition period. The design was not a formal extension trial with continued randomization. It was an observational continuation that tracked outcomes as the placebo group crossed over to active therapy.

During the open-label phase, participants who had been on placebo and then started rosuvastatin experienced rapid reductions in both LDL cholesterol and hsCRP. Their event rates began converging with the original rosuvastatin group. This finding supported two conclusions: the benefit was real (not a statistical artifact of early stopping), and the mechanism appeared tied to measurable biomarker changes rather than chance imbalance at randomization.

The combined in-trial and post-trial data showed that for every 25 patients treated with rosuvastatin for five years, one major CV event would be prevented. The NNT of 25 over five years positioned rosuvastatin favorably compared with other primary-prevention interventions in this risk stratum.

Durability of LDL and hsCRP Reductions

Within the original trial, rosuvastatin reduced LDL cholesterol by 50% (from a median of 108 mg/dL to 55 mg/dL) and hsCRP by 37%. A question that persisted after publication was whether hsCRP reduction independently contributed to the benefit or merely tracked alongside LDL lowering.

A prespecified secondary analysis separated participants who achieved both low LDL (<70 mg/dL) and low hsCRP (<2 mg/L) from those who achieved only one target. The group reaching both thresholds had event rates significantly lower than those reaching only one, with hazard ratios suggesting additive benefit from dual biomarker reduction. This analysis was not powered as a standalone trial, but it generated the hypothesis that anti-inflammatory effects of statins carry independent clinical weight, a question later tested directly in the CANTOS trial with canakinumab.

Post-trial lipid data confirmed that rosuvastatin's LDL-lowering effect remained stable through open-label follow-up. There was no evidence of tachyphylaxis or loss of efficacy with continued use, consistent with the broader CTT Collaboration meta-analysis showing that statin benefit scales linearly with LDL reduction over at least five years.

The Diabetes Signal

The most consequential safety finding from JUPITER's extended data was a statistically significant increase in physician-reported diabetes. In the primary publication, 270 participants in the rosuvastatin group versus 216 in the placebo group reported new diabetes diagnoses (p = 0.01). The absolute difference was small (3.0% vs. 2.4% over 1.9 years), but the signal was clear.

Subsequent analysis by Ridker and colleagues in 2012 examined this signal in detail. Participants who developed diabetes on rosuvastatin overwhelmingly had baseline risk factors for diabetes: impaired fasting glucose, metabolic syndrome, elevated BMI, or elevated HbA1c. Among those with zero baseline diabetes risk factors, the incidence of new diabetes was not significantly different between rosuvastatin and placebo.

A large meta-analysis by Sattar et al. pooled JUPITER with 12 other statin trials (91,140 participants total) and calculated a 9% relative increase in diabetes risk across all statins. The absolute risk was roughly one additional diabetes case per 255 patients treated for four years. For JUPITER specifically, the CV benefit outweighed the diabetes risk: for every new diabetes case, roughly 3.4 major CV events were prevented.

This finding changed clinical practice. The FDA updated the rosuvastatin label to include warnings about increased HbA1c and fasting glucose. Clinicians began screening more carefully for prediabetes before initiating high-intensity statin therapy in primary-prevention populations.

Early Termination Controversy

Several independent groups questioned whether JUPITER's early termination inflated the treatment effect. De Lorgeril and colleagues published a critical reanalysis arguing that the mortality benefit disappeared in the final months of follow-up and that the trial's commercial sponsorship by AstraZeneca created incentive to stop at the point of maximum apparent benefit.

The JUPITER investigators responded with additional analyses. Glynn et al. demonstrated that the treatment effect was consistent across prespecified subgroups and time intervals, and that the hazard ratio did not meaningfully change when later accruing events were included. They also noted that the stopping rules were established before the trial began and were applied by an independent monitoring board.

The truth likely sits between these positions. Early termination does, on average, overestimate effects by 20 to 30% in cardiovascular trials. If JUPITER's true hazard ratio were 0.65 rather than 0.56, the therapy would still represent a clinically meaningful 35% reduction. The CV benefit was real. The debate was about its precise magnitude.

Impact on Guidelines and Prescribing

JUPITER's results, including the follow-up data, directly influenced the 2013 ACC/AHA cholesterol guidelines. Those guidelines moved away from LDL targets and toward a risk-based approach. Adults with a 10-year ASCVD risk of 5 to 7.5% could now be considered for moderate- to high-intensity statin therapy, a population that overlapped substantially with JUPITER's enrollment criteria.

The USPSTF followed in 2016 with a B recommendation for statin use in adults aged 40, 75 with at least one CV risk factor and a 10-year ASCVD risk ≥10%. JUPITER was cited as a key trial supporting the extension of primary-prevention statin use to populations previously considered too low-risk for pharmacotherapy.

In 2010, the FDA approved an expanded indication for rosuvastatin specifically for primary prevention in men ≥50 and women ≥60 with hsCRP ≥2 mg/L plus at least one additional risk factor. This made rosuvastatin the first statin with an explicit primary-prevention indication tied to an inflammatory biomarker.

Limitations the Original Authors Acknowledged

The JUPITER investigators were transparent about several constraints that the post-trial data could not fully resolve:

| Limitation | Post-trial status | |---|---| | Short median follow-up (1.9 yr) | Open-label extension added ~2 years, but crossover contaminated the comparison | | Physician-reported diabetes (no protocol-mandated OGTT) | Confirmed by meta-analysis but diagnostic rigor remains a concern | | Homogeneous population (mostly White, North American/European) | No follow-up studies in more diverse cohorts with the same CRP-based enrollment | | Sponsor involvement (AstraZeneca) | Independent reanalyses reached broadly similar conclusions on CV endpoints | | hsCRP as enrollment criterion vs. treatment target | CANTOS later validated inflammation hypothesis, but CRP-guided statin therapy is still not standard |

What Clinicians Should Take Away

The post-trial data strengthened three conclusions about JUPITER. Rosuvastatin 20 mg reduces major CV events in primary-prevention patients selected by elevated hsCRP, and that benefit is durable when therapy continues. The diabetes signal is real, concentrated in patients with pre-existing metabolic risk, and manageable with baseline screening. The early-termination debate, while legitimate, does not erase the treatment effect.

For patients with elevated hsCRP, normal LDL, and no strong diabetes risk factors, JUPITER's data (original and extended) supports statin initiation. For patients with prediabetes or metabolic syndrome, the conversation requires weighing a modest acceleration of diabetes onset against a meaningful reduction in heart attack and stroke risk.

Frequently asked questions

›

References

Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207. PubMed
Ridker PM, Danielson E, Fonseca FAH, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373(9670):1175-1182. PubMed
Ridker PM, Pradhan A, MacFadyen JG, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380(9841):565-571. PubMed
Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735-742. PubMed
de Lorgeril M, Salen P, Abramson J, et al. Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy. Arch Intern Med. 2010;170(12):1032-1036. PubMed
Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol. J Am Coll Cardiol. 2014;63(25 Pt B):2889-2934. PubMed
Crestor (rosuvastatin calcium) prescribing information. U.S. Food and Drug Administration. FDA Label